New Study Confirms Daxor’s BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients
March 23, 2023 08:30 ET
|
Daxor Corporation
Commonly Used Pressure Measure for Volume Assessment Discordant with Direct Measurement by BVA Oak Ridge, TN, March 23, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in...
Pilot Randomized Controlled Trial Validates Daxor BVA-100® Diagnostic for Heart Failure Patients
March 23, 2023 08:00 ET
|
Daxor Corporation
BVA Feasibly Guides Fluid Management with Greater Accuracy than Traditional MeansResearchers Conclude that a Larger Powered RCT is Warranted Oak Ridge, TN, March 23, 2023 (GLOBE NEWSWIRE) -- Daxor...
Daxor Corporation to Present at the H.C. Wainwright & Company Global Investment Conference
May 12, 2022 08:00 ET
|
Daxor Corporation
NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will...
New Data Validates Blood Volume Analysis Guided-Care, Improves Survival in Patients with Advanced Heart Failure Supported with Left Ventricular Assist Device
May 02, 2022 08:00 ET
|
Daxor Corporation
Study Presented at the International Society for Heart and Lung Transplant 42nd Annual Meeting and Scientific Sessions 2022 Oak Ridge, TN, May 02, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation...
New Study from Duke Heart Demonstrates the Unique Accuracy and Utility of Daxor’s Blood Volume Diagnostic (BVA-100®) for Improving Worsening Heart Failure
April 06, 2022 08:00 ET
|
Daxor Corporation
Study Presented at the 71st Annual American College of Cardiology Meeting Oak Ridge, TN, April 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume...
Daxor Corporation to Participate in the Maxim Group 2022 Virtual Growth Conference
March 23, 2022 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, March 23, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces that President and CEO Michael Feldschuh will...
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
March 01, 2022 09:00 ET
|
Daxor Corporation
Oak Ridge, TN, March 01, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today issued a corporate update in a Letter to...
Daxor Corporation Announces $1.35 Per Share NAV Increase and Files Annual Report for Fiscal 2021
March 01, 2022 08:00 ET
|
Daxor Corporation
Revenues of Operating Division Increase by 70.6% Oak Ridge, TN, March 01, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, filed...
Daxor Corporation Commences Trading on The NASDAQ Capital Market
February 02, 2022 08:00 ET
|
Daxor Corporation
Management to Ring the Nasdaq Stock Market Opening Bell on February 4, 2022 Oak Ridge, TN, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume...
Daxor Corporation Announces $0.48 Per Share NAV Increase and Files Annual Report for Fiscal 2020
February 26, 2021 08:30 ET
|
Daxor Corporation
Revenues of Operating Division Increase by 50.4% NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) The global leader in blood volume technology today filed its Annual...